

**Galapagos: webinar “UC The Future” IBD: Innovate. Build. Discover.**  
Interesting webinar with Dr Séverine Vermeire, Onno van de Stolpe and Dr Mark C. Genovese about IBD/UC.

The screenshot shows the top portion of a webinar interface. At the top left is the GILEAD | Galapagos logo. To its right is the main title: **Innovate. Build. Discover.** with the subtitle **UC the future** below it. The central area features a large graphic of a bird in flight within a circular frame, with the text **Innovate. Build. Discover.** and **UC the future** overlaid, followed by **will be starting shortly**. On the right side, there is a vertical list of speaker bios, each with a circular profile picture and a right-pointing arrow. The bios are for Séverine Vermeire, MD PhD (Full Professor of Medicine, Head of the Department of Chronic Diseases, Metabolism (CHROMETA), KU Leuven), Onno van de Stolpe (CEO and Founder Galapagos NV), and Mark C. Genovese, MD (SVP for Inflammation Clinical Research, Gilead Sciences). Below the title slide is a text input field with the placeholder "Enter your question \*" and a green "Submit" button. At the bottom center is a control bar with icons for video, chat, screen share, and help. The bottom right corner features the text "POWERED BY CN24".

Mark en Onno explained their collaboration and commitment to IBD. Séverine Vermeire (KU Leuven) explained why innovation is still essential in UC and the how the JAK-STAT pathway (selective JAK's) are promising with regards to the remaining considerable unmet needs.

This screenshot shows the same webinar interface as above, but with a grid of four video feeds. The top-left feed shows Onno van de Stolpe, the top-right shows Séverine Vermeire, the bottom-left shows Mark C. Genovese, and the bottom-right shows a woman with glasses. The speaker bios on the right and the "Enter your question \*" field with the "Submit" button are still visible. The control bar at the bottom and the "POWERED BY CN24" logo are also present.

GILEAD | Galapagos **Innovate. Build. Discover.**  
UC the future

Séverine Vermeire, MD PhD  
Full Professor of Medicine, Head of the Department of Chronic Diseases, Metabolism (CHROMETA) KU Leuven

Onno van de Stolpe  
CEO and Founder Galapagos NV

Mark C. Genovese, MD  
SVP for Inflammation Clinical Research Gilead Sciences

Enter your question \*

Submit

Powered by ON24

Next week on UEG week (Symposium Galapagos & Gilead on Monday October 12th) final results of the Selection Phase3 study (Filgotinib in UC) will be presented.

#### Q&A: Toledo

**Round Table on October 27th: great event!** Data, targets, results preclinical trials 2 Phase2 studies started recently (SEA TURTLE, LADYBUG).  
**3 other Phase2 studies will be launched before end of the year.**

GILEAD | Galapagos **Innovate. Build. Discover.**  
UC the future

Séverine Vermeire, MD PhD  
Full Professor of Medicine, Head of the Department of Chronic Diseases, Metabolism (CHROMETA) KU Leuven

Onno van de Stolpe  
CEO and Founder Galapagos NV

Mark C. Genovese, MD  
SVP for Inflammation Clinical Research Gilead Sciences

Enter your question \*

Submit

Powered by ON24

**GILEAD | Galapagos** **Innovate. Build. Discover.**  
UC the future

**Séverine Vermeire, MD PhD**  
Full Professor of Medicine, Head of the Department of Chronic Diseases, Metabolism (CHROMETA) KU Leuven

**Onno van de Stolpe**  
CEO and Founder Galapagos NV

**Mark C. Genovese, MD**  
SVP for Inflammation Clinical Research Gilead Sciences

Enter your question\*  
Submit

POWERED BY CN24

JAK inhibitors in IBD: promising in UC and CD.

MD PhD Séverine Vermeire: Avoid JAK2. (Selective) JAK1, JAK3 and TYK2 are preferable.

Collaboration Galapagos-Gilead: Addressing unmet needs in immune-mediated inflammatory diseases requires innovative approaches.

**GILEAD | Galapagos** **Innovate. Build. Discover.**  
UC the future

**Addressing unmet needs in immune-mediated inflammatory diseases requires innovative approaches<sup>1-3</sup>**

Molecules in virology, oncology and inflammation

Molecules in inflammation

Phase 2 & 3 studies for JAK1 pathway inhibitors

10 YEAR GIL GALAPAGOS

A new era in transformative research has begun

**Séverine Vermeire, MD PhD**  
Full Professor of Medicine, Head of the Department of Chronic Diseases, Metabolism (CHROMETA) KU Leuven

**Onno van de Stolpe**  
CEO and Founder Galapagos NV

**Mark C. Genovese, MD**  
SVP for Inflammation Clinical Research Gilead Sciences

Enter your question\*  
Submit

POWERED BY CN24



**But we're just getting started**

Disease: Phase 1, Phase 2, Phase 3

Our 10-year plan to beat inflammation

- Combine resources, infrastructure, and experience to:
  - accelerate our drug discovery
  - investigate potential new therapies for RA, IBD, and other inflammatory diseases

Clinical trials in multiple molecules for IBD:

- Phase 3: UC and CD
- Phase 2: Small bowel and perianal Crohn's CD

Speakers:

- Séverine Vermeire, MD PhD  
Full Professor of Medicine, Head of the Department of Chronic Diseases, Metabolism (CHROMETA)  
KU Leuven
- Onno van de Stolpe  
CEO and Founder  
Galapagos NV
- Mark C. Genovese, MD  
SVP for Inflammation Clinical Research  
Gilead Sciences

Enter your question:

Submit

Powered by CN24

But we're just getting started.

JAK inhibitors reduce the activity of multiple cytokines implicated in IBD pathogenesis

**JAK inhibitors reduce the activity of multiple cytokines implicated in IBD pathogenesis<sup>1-3</sup>**

Cytokines: IL-6, IL-23, IL-12/23, IL-17, IL-1, IL-18, IL-25, IL-31, IL-35, IL-36, IL-37, IL-38, IL-39, IL-40, IL-41, IL-42, IL-43, IL-44, IL-45, IL-46, IL-47, IL-48, IL-49, IL-50, IL-51, IL-52, IL-53, IL-54, IL-55, IL-56, IL-57, IL-58, IL-59, IL-60, IL-61, IL-62, IL-63, IL-64, IL-65, IL-66, IL-67, IL-68, IL-69, IL-70, IL-71, IL-72, IL-73, IL-74, IL-75, IL-76, IL-77, IL-78, IL-79, IL-80, IL-81, IL-82, IL-83, IL-84, IL-85, IL-86, IL-87, IL-88, IL-89, IL-90, IL-91, IL-92, IL-93, IL-94, IL-95, IL-96, IL-97, IL-98, IL-99, IL-100, IL-101, IL-102, IL-103, IL-104, IL-105, IL-106, IL-107, IL-108, IL-109, IL-110, IL-111, IL-112, IL-113, IL-114, IL-115, IL-116, IL-117, IL-118, IL-119, IL-120, IL-121, IL-122, IL-123, IL-124, IL-125, IL-126, IL-127, IL-128, IL-129, IL-130, IL-131, IL-132, IL-133, IL-134, IL-135, IL-136, IL-137, IL-138, IL-139, IL-140, IL-141, IL-142, IL-143, IL-144, IL-145, IL-146, IL-147, IL-148, IL-149, IL-150, IL-151, IL-152, IL-153, IL-154, IL-155, IL-156, IL-157, IL-158, IL-159, IL-160, IL-161, IL-162, IL-163, IL-164, IL-165, IL-166, IL-167, IL-168, IL-169, IL-170, IL-171, IL-172, IL-173, IL-174, IL-175, IL-176, IL-177, IL-178, IL-179, IL-180, IL-181, IL-182, IL-183, IL-184, IL-185, IL-186, IL-187, IL-188, IL-189, IL-190, IL-191, IL-192, IL-193, IL-194, IL-195, IL-196, IL-197, IL-198, IL-199, IL-200, IL-201, IL-202, IL-203, IL-204, IL-205, IL-206, IL-207, IL-208, IL-209, IL-210, IL-211, IL-212, IL-213, IL-214, IL-215, IL-216, IL-217, IL-218, IL-219, IL-220, IL-221, IL-222, IL-223, IL-224, IL-225, IL-226, IL-227, IL-228, IL-229, IL-230, IL-231, IL-232, IL-233, IL-234, IL-235, IL-236, IL-237, IL-238, IL-239, IL-240, IL-241, IL-242, IL-243, IL-244, IL-245, IL-246, IL-247, IL-248, IL-249, IL-250, IL-251, IL-252, IL-253, IL-254, IL-255, IL-256, IL-257, IL-258, IL-259, IL-260, IL-261, IL-262, IL-263, IL-264, IL-265, IL-266, IL-267, IL-268, IL-269, IL-270, IL-271, IL-272, IL-273, IL-274, IL-275, IL-276, IL-277, IL-278, IL-279, IL-280, IL-281, IL-282, IL-283, IL-284, IL-285, IL-286, IL-287, IL-288, IL-289, IL-290, IL-291, IL-292, IL-293, IL-294, IL-295, IL-296, IL-297, IL-298, IL-299, IL-300, IL-301, IL-302, IL-303, IL-304, IL-305, IL-306, IL-307, IL-308, IL-309, IL-310, IL-311, IL-312, IL-313, IL-314, IL-315, IL-316, IL-317, IL-318, IL-319, IL-320, IL-321, IL-322, IL-323, IL-324, IL-325, IL-326, IL-327, IL-328, IL-329, IL-330, IL-331, IL-332, IL-333, IL-334, IL-335, IL-336, IL-337, IL-338, IL-339, IL-340, IL-341, IL-342, IL-343, IL-344, IL-345, IL-346, IL-347, IL-348, IL-349, IL-350, IL-351, IL-352, IL-353, IL-354, IL-355, IL-356, IL-357, IL-358, IL-359, IL-360, IL-361, IL-362, IL-363, IL-364, IL-365, IL-366, IL-367, IL-368, IL-369, IL-370, IL-371, IL-372, IL-373, IL-374, IL-375, IL-376, IL-377, IL-378, IL-379, IL-380, IL-381, IL-382, IL-383, IL-384, IL-385, IL-386, IL-387, IL-388, IL-389, IL-390, IL-391, IL-392, IL-393, IL-394, IL-395, IL-396, IL-397, IL-398, IL-399, IL-400, IL-401, IL-402, IL-403, IL-404, IL-405, IL-406, IL-407, IL-408, IL-409, IL-410, IL-411, IL-412, IL-413, IL-414, IL-415, IL-416, IL-417, IL-418, IL-419, IL-420, IL-421, IL-422, IL-423, IL-424, IL-425, IL-426, IL-427, IL-428, IL-429, IL-430, IL-431, IL-432, IL-433, IL-434, IL-435, IL-436, IL-437, IL-438, IL-439, IL-440, IL-441, IL-442, IL-443, IL-444, IL-445, IL-446, IL-447, IL-448, IL-449, IL-450, IL-451, IL-452, IL-453, IL-454, IL-455, IL-456, IL-457, IL-458, IL-459, IL-460, IL-461, IL-462, IL-463, IL-464, IL-465, IL-466, IL-467, IL-468, IL-469, IL-470, IL-471, IL-472, IL-473, IL-474, IL-475, IL-476, IL-477, IL-478, IL-479, IL-480, IL-481, IL-482, IL-483, IL-484, IL-485, IL-486, IL-487, IL-488, IL-489, IL-490, IL-491, IL-492, IL-493, IL-494, IL-495, IL-496, IL-497, IL-498, IL-499, IL-500, IL-501, IL-502, IL-503, IL-504, IL-505, IL-506, IL-507, IL-508, IL-509, IL-510, IL-511, IL-512, IL-513, IL-514, IL-515, IL-516, IL-517, IL-518, IL-519, IL-520, IL-521, IL-522, IL-523, IL-524, IL-525, IL-526, IL-527, IL-528, IL-529, IL-530, IL-531, IL-532, IL-533, IL-534, IL-535, IL-536, IL-537, IL-538, IL-539, IL-540, IL-541, IL-542, IL-543, IL-544, IL-545, IL-546, IL-547, IL-548, IL-549, IL-550, IL-551, IL-552, IL-553, IL-554, IL-555, IL-556, IL-557, IL-558, IL-559, IL-560, IL-561, IL-562, IL-563, IL-564, IL-565, IL-566, IL-567, IL-568, IL-569, IL-570, IL-571, IL-572, IL-573, IL-574, IL-575, IL-576, IL-577, IL-578, IL-579, IL-580, IL-581, IL-582, IL-583, IL-584, IL-585, IL-586, IL-587, IL-588, IL-589, IL-590, IL-591, IL-592, IL-593, IL-594, IL-595, IL-596, IL-597, IL-598, IL-599, IL-600, IL-601, IL-602, IL-603, IL-604, IL-605, IL-606, IL-607, IL-608, IL-609, IL-610, IL-611, IL-612, IL-613, IL-614, IL-615, IL-616, IL-617, IL-618, IL-619, IL-620, IL-621, IL-622, IL-623, IL-624, IL-625, IL-626, IL-627, IL-628, IL-629, IL-630, IL-631, IL-632, IL-633, IL-634, IL-635, IL-636, IL-637, IL-638, IL-639, IL-640, IL-641, IL-642, IL-643, IL-644, IL-645, IL-646, IL-647, IL-648, IL-649, IL-650, IL-651, IL-652, IL-653, IL-654, IL-655, IL-656, IL-657, IL-658, IL-659, IL-660, IL-661, IL-662, IL-663, IL-664, IL-665, IL-666, IL-667, IL-668, IL-669, IL-670, IL-671, IL-672, IL-673, IL-674, IL-675, IL-676, IL-677, IL-678, IL-679, IL-680, IL-681, IL-682, IL-683, IL-684, IL-685, IL-686, IL-687, IL-688, IL-689, IL-690, IL-691, IL-692, IL-693, IL-694, IL-695, IL-696, IL-697, IL-698, IL-699, IL-700, IL-701, IL-702, IL-703, IL-704, IL-705, IL-706, IL-707, IL-708, IL-709, IL-710, IL-711, IL-712, IL-713, IL-714, IL-715, IL-716, IL-717, IL-718, IL-719, IL-720, IL-721, IL-722, IL-723, IL-724, IL-725, IL-726, IL-727, IL-728, IL-729, IL-730, IL-731, IL-732, IL-733, IL-734, IL-735, IL-736, IL-737, IL-738, IL-739, IL-740, IL-741, IL-742, IL-743, IL-744, IL-745, IL-746, IL-747, IL-748, IL-749, IL-750, IL-751, IL-752, IL-753, IL-754, IL-755, IL-756, IL-757, IL-758, IL-759, IL-760, IL-761, IL-762, IL-763, IL-764, IL-765, IL-766, IL-767, IL-768, IL-769, IL-770, IL-771, IL-772, IL-773, IL-774, IL-775, IL-776, IL-777, IL-778, IL-779, IL-780, IL-781, IL-782, IL-783, IL-784, IL-785, IL-786, IL-787, IL-788, IL-789, IL-790, IL-791, IL-792, IL-793, IL-794, IL-795, IL-796, IL-797, IL-798, IL-799, IL-800, IL-801, IL-802, IL-803, IL-804, IL-805, IL-806, IL-807, IL-808, IL-809, IL-810, IL-811, IL-812, IL-813, IL-814, IL-815, IL-816, IL-817, IL-818, IL-819, IL-820, IL-821, IL-822, IL-823, IL-824, IL-825, IL-826, IL-827, IL-828, IL-829, IL-830, IL-831, IL-832, IL-833, IL-834, IL-835, IL-836, IL-837, IL-838, IL-839, IL-840, IL-841, IL-842, IL-843, IL-844, IL-845, IL-846, IL-847, IL-848, IL-849, IL-850, IL-851, IL-852, IL-853, IL-854, IL-855, IL-856, IL-857, IL-858, IL-859, IL-860, IL-861, IL-862, IL-863, IL-864, IL-865, IL-866, IL-867, IL-868, IL-869, IL-870, IL-871, IL-872, IL-873, IL-874, IL-875, IL-876, IL-877, IL-878, IL-879, IL-880, IL-881, IL-882, IL-883, IL-884, IL-885, IL-886, IL-887, IL-888, IL-889, IL-890, IL-891, IL-892, IL-893, IL-894, IL-895, IL-896, IL-897, IL-898, IL-899, IL-900, IL-901, IL-902, IL-903, IL-904, IL-905, IL-906, IL-907, IL-908, IL-909, IL-910, IL-911, IL-912, IL-913, IL-914, IL-915, IL-916, IL-917, IL-918, IL-919, IL-920, IL-921, IL-922, IL-923, IL-924, IL-925, IL-926, IL-927, IL-928, IL-929, IL-930, IL-931, IL-932, IL-933, IL-934, IL-935, IL-936, IL-937, IL-938, IL-939, IL-940, IL-941, IL-942, IL-943, IL-944, IL-945, IL-946, IL-947, IL-948, IL-949, IL-950, IL-951, IL-952, IL-953, IL-954, IL-955, IL-956, IL-957, IL-958, IL-959, IL-960, IL-961, IL-962, IL-963, IL-964, IL-965, IL-966, IL-967, IL-968, IL-969, IL-970, IL-971, IL-972, IL-973, IL-974, IL-975, IL-976, IL-977, IL-978, IL-979, IL-980, IL-981, IL-982, IL-983, IL-984, IL-985, IL-986, IL-987, IL-988, IL-989, IL-990, IL-991, IL-992, IL-993, IL-994, IL-995, IL-996, IL-997, IL-998, IL-999, IL-1000.

Speakers:

- Séverine Vermeire, MD PhD  
Full Professor of Medicine, Head of the Department of Chronic Diseases, Metabolism (CHROMETA)  
KU Leuven
- Onno van de Stolpe  
CEO and Founder  
Galapagos NV
- Mark C. Genovese, MD  
SVP for Inflammation Clinical Research  
Gilead Sciences

Enter your question:

Submit

Powered by CN24

**GILEAD | Galapagos** **Innovate. Build. Discover.**  
UC the future

### Filgotinib ▼: JAK1-preferential inhibitor

Filgotinib: Results from the Phase III SELECTION trial

- "Filgotinib 200 mg achieved all primary endpoints in the study, inducing clinical remission at Week 10 and maintaining clinical remission at Week 58 in a significantly higher proportion of patients compared with placebo."
- "Filgotinib 100 mg did not achieve statistically significant clinical remission at Week 10."
- "Rates of serious infections, herpes zoster, venous thrombosis, pulmonary embolism and gastrointestinal perforations were low and comparable across treatment groups in both the induction and maintenance phases of the study."

Full results of the SELECTION trial will be presented at UEG Week 2020!

**Séverine Vermeire, MD PhD**  
Full Professor of Medicine, Head of the Department of Chronic Diseases, Metabolism (CHROMETA) KU Leuven

**Onno van de Stolpe**  
CEO and Founder Galapagos NV

**Mark C. Genovese, MD**  
SVP for Inflammation Clinical Research, Gilead Sciences

Enter your question!

Submit

Presented by **CN24**

### Filgotinib: JAK1-preferential inhibitor.

Full results of the SELECTION trial will be presented at UEG Week 2020!

**GILEAD | Galapagos** **Innovate. Build. Discover.**  
UC the future

Thank you for attending  
**Innovate. Build. Discover.**  
UC the future

Please visit  
[hosted.bmj.com/futureofuc](https://hosted.bmj.com/futureofuc)  
for more information on Gilead and Galapagos' activities at UEG Week Virtual, including late breakers and the symposium

**Séverine Vermeire, MD PhD**  
Full Professor of Medicine, Head of the Department of Chronic Diseases, Metabolism (CHROMETA) KU Leuven

**Onno van de Stolpe**  
CEO and Founder Galapagos NV

**Mark C. Genovese, MD**  
SVP for Inflammation Clinical Research, Gilead Sciences

Enter your question!

Submit

Presented by **CN24**

Webinar "UC the future" Thank you for attending.

For more information on Gilead and Galapagos' activities: UEG Week Virtual, including late breakers and the symposium please visit: <https://hosted.bmj.com/futureofuc>